Finally, some ALK compound mutations, like L1198F + C1156Y confer resistance to lorlatinib through steric interference with the drug binding but paradoxically enhance binding to crizotinib and resensitize cancer cells to polder ALK inhibitors [19]. This evidence concerns the gene ALK and cancer.